• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

This Virus Infects Around 95 Percent Of Us – And Its Weak Spots Have Now Been Found

March 13, 2024 by Deborah Bloomfield

Epstein-Barr Virus (EBV) has no available vaccine or cure – but that may not be the case forever. New research has uncovered some of the virus’s vulnerabilities, opening the door to the possibility of targeted treatment.

You are probably infected with EBV. It’s overwhelmingly prevalent in the human population, estimated to have infected around 95 percent of us, yet most people would never know they had it. However, when it does decide to rear its head, it’s associated with some fairly nasty diseases including mononucleosis (sometimes called glandular fever), multiple sclerosis, and some cancers.  

Advertisement

A lot of effort has gone into developing a vaccine for EBV, but as of now there isn’t one available, and we also don’t have any specific treatments for the virus.

Despite how widespread it is, and how serious its effects can be, EBV was only discovered in 1964 by Dr Anthony Epstein –who recently passed away aged 102 – and his then-doctoral student Yvonne Barr. At the time, it was groundbreaking – no cancer-causing virus had ever been identified before. Since then, we’ve learned of others like the human papillomavirus (HPV), for which we even have a very effective vaccine. However, EBV is still stubbornly resistant to treatment.

Thanks to a new study, that could be about to change. Investigators at the National Institute of Allergy and Infectious Diseases (NIAID) examined a protein called gp42 which EBV uses to infect B cells, a type of white blood cell, in which the virus can sit quite happily for the remainder of a person’s life.

The team developed two monoclonal antibodies targeting gp42, called A10 and 4C12. The aim is to stop the protein from binding to or fusing with the B cells, preventing the virus from getting in there in the first place.

Advertisement

X-ray crystallography revealed that the two antibodies were interacting with two different sites on the gp42 protein. To investigate how this could impact EBV infection, the team performed experiments on mice using A10, 4C12, and several other antibodies. A10 came out on top: it almost completely blocked infection and none of the treated mice developed lymphoma, one of the cancers associated with EBV.

While still limited to mice for now, the results are promising. If further research shows a similar effect in humans, A10 could be a promising preventative option for people not yet infected with EBV. It could also be a game-changer for people with compromised immune systems, due to illness or transplant surgery for example. These individuals are at particular risk of severe disease caused by EBV, which can even be fatal.

Having identified the weak spots on the gp42 protein, scientists could also now go on to design vaccines that generate antibodies to one or both of the sites, giving the human immune system the chance to mount its own response against this ubiquitous threat.

The study is published in the journal Immunity.

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. Kroger expects smaller decline in same-store sales on grocery demand
  2. Libya presidency council head plans to hold October conference
  3. Cold Water Therapy: What Are The Benefits And Dangers Of Ice Baths, Wild Swimming And Freezing Showers?
  4. If Enceladus Or Europa Have Life It Might Be Easy To Find

Source Link: This Virus Infects Around 95 Percent Of Us – And Its Weak Spots Have Now Been Found

Filed Under: News

Primary Sidebar

  • Interstellar Comet 3I/ATLAS Is Back From Behind The Sun – Still Not An Alien Spacecraft, Though
  • Bowhead Whales Can Live For 200 Years – This May Explain Their Extraordinary Longevity
  • Trump Orders First Nuclear Weapons Test In The US Since 1992 – Here’s What You Need To Know
  • Tiny Triceratops-Tackling Tyrannosaur Was Its Own Species, Not A Baby T. Rex
  • What Makes Ammolite Gemstones, A Rare Kind Of Fossilized Ammonite, So Vibrant? It’s All In The Nacre
  • Something Melted This Tesla’s Windscreen. Could It Have Been A World-First Meteorite Collision?
  • Carnivorous “Death-Ball” Sponge Among 30 New Deep-Sea Weirdos Discovered In The Southern Ocean
  • Chimps Can Revise Beliefs When Confronted With Conflicting Evidence. Can You?
  • Explosive Airbursts, Like Tunguska, Might Be Hiding Among “Halloween Fireballs” Meteor Shower
  • One Of The World’s Rarest Penguins Is Actually Three Subspecies In A Trench Coat
  • “I Am The Allergen”: The Super-Rare Condition That Makes Everyone Else Allergic To You
  • 42,000-Year-Old Yellow Crayon Suggests Neanderthals Created Art – And It’s Still Sharp Too
  • IFLScience Investigates The Loch Ness Monster: A Round-Up Of Our Spooky Season Nessie Deep Dive
  • Why An Eastern Pacific Tear In Earth’s Crust Could Spare The Pacific Northwest… Eventually
  • JWST Reveals Never-Before-Seen Details Of The Red Spider Nebula And It’s Spectacular
  • “Breaking Records By Extraordinary Margins”: 22 Of Earth’s 34 Vital Signs At Record Levels
  • “The Most Important Unsolved Problem In Pure Math”: Where Is Humanity At With Prime Numbers?
  • The “Great Halloween Solar Storms”: 22 Years Ago, One Of The Most Powerful CMEs Ever Hit Earth
  • IFLScience Investigates The Loch Ness Monster: A Documentary On The Science, The Story, And The Power Of Belief
  • Remarkably Preserved 23-Million-Year-Old “Frosty” Rhino Discovered In Canadian Arctic
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version